FDA Patient Network’s Inaugural Meeting Seeks Input In Regulatory Decision-Making

In the shadow of final negotiations over PDUFA reauthorization, the agency is inviting patients, their representatives, industry and academics to discuss how best to use patient input in decisions on regulated drugs, devices and biologics.

FDA’s latest move to integrate patient input into regulatory decision-making on drugs, devices and biologics is a May 18 meeting to be held at the agency’s White Oak, Silver Spring, Md. headquarters.

The agency says it will welcome patients, caregivers, independent patient advocates, patient advocate groups, academics, industry representatives and health professional groups to the meeting

More from United States

More from North America